Adynxx Inc. used the same measure to select trial patients as other pain drug developers have used to weed them out – the Pain Catastrophizing Scale (PCS) – and arrived at what the company is calling a phase II success that greases the skids for a non-opioid phase III in a hard-to-treat patient sector.